NCT02682641 2024-02-26
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Unknown
Clinical Trials
109 trialsNCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
NCT06164327 2023-12-11
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 1 Unknown
NCT05290090 2023-10-17
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05979948 2023-09-14
CZ-WM01
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05887726 2023-07-27
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05940051 2023-07-11
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05923879 2023-06-28
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
Unknown
NCT04578613 2023-06-05
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT05179733 2023-05-23
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Phase 3 Unknown
NCT04433156 2023-05-18
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT05073250 2023-05-12
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT02632396 2023-05-09
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission
Emory University
Phase 1/2 Unknown
NCT03688451 2023-03-29
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
University of Cincinnati
Phase 2 Unknown
NCT05784987 2023-03-27
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT05777369 2023-03-21
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT05498259 2023-02-03
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01811368 2022-11-30
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Unknown
NCT05575973 2022-10-12
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Phase 2 Unknown
NCT05504603 2022-08-17
Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04507477 2022-08-02
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
University Health Network, Toronto
Phase 1/2 Unknown
NCT03736616 2022-07-22
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Phase 2 Unknown
NCT05379647 2022-05-18
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
Phase 1 Unknown
NCT05332587 2022-05-02
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Unknown
NCT04058470 2022-04-14
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT05191225 2022-03-31
Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study
Bioaraba Health Research Institute
Phase 4 Unknown
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04989621 2022-03-24
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Phase 2 Unknown
NCT05200312 2022-03-11
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT05049473 2021-09-20
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Phase 2 Unknown
NCT04994626 2021-08-06
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
ChineseAMS
Phase 2 Unknown
NCT00790413 2021-02-21
Haploidentical Stem Cell Transplantation in Neuroblastoma
Lund University Hospital
Phase EARLY_PHASE1 Unknown
NCT03949062 2021-02-17
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04622579 2020-11-10
R2DLBCL80
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT03778619 2020-07-28
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
GC Cell Corporation
Phase 1/2 Unknown
NCT04425824 2020-06-16
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
ChineseAMS
Phase 2 Unknown
NCT04432402 2020-06-16
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT04127916 2020-03-18
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)
Samsung Medical Center
Unknown
NCT02951728 2020-03-11
DR-CHOP
Ruijin Hospital
Phase 1/2 Unknown
NCT01619761 2020-02-11
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT03746223 2019-10-09
Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT03777085 2019-05-30
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT01670370 2019-02-15
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown